Sbir topic 294 phase 1 - development of glycosylation - specific research

Ended Definitive Contract Awarded Last action

Contract number
HHSN261201100077C
Awardee
Awarding agency
Obligated
$149,919

Award facts

Contract value 100% obligated
$149,919.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 14 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Houston, TX 77054, USA
Research
SBIR Program Phase I Action

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action 3 $0
Other Administrative Action 2 $0
Other Administrative Action 1 $0
Original award $149,919

About this award

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Biotex, Inc. The contract is for the development of glycosylation-specific research, with a ceiling value of $149,919.00 and a completion date of October 14, 2012. The contract is a definitive contract with a firm fixed-price pricing type. This SBIR Phase I action is a set-aside for small businesses.

Quick answers

Who was awarded contract HHSN261201100077C?

HHSN261201100077C was awarded to Biotex, Inc. by National Cancer Institute (National Institutes of Health) on September 15, 2011.

How much is contract HHSN261201100077C worth?

The government has obligated $149,919 on HHSN261201100077C.

Was contract HHSN261201100077C competed?

The extent of competition for HHSN261201100077C was full and open competition after exclusion of sources. The government received 14 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award